Drug
Vir 5818
Vir 5818: highest development phase Phase 1/2, developed by Vir Biotechnology, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Vir Biotechnology, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| VIR-5818 NCT05356741 | Phase 1/2 | Locally Advanced or Metastatic HER2-Expressing Cancers |
Latest
No recent events.
Follow Vir 5818 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.